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Abstract
Background Interruption of antithrombotic treatment before
surgery may prevent bleeding, but at the price of increasing
cardiovascular complications. This prospective study
analysed the impact of antithrombotic therapy interruption
on outcomes in non-selected surgical patients with known
cardiovascular disease (CVD).
Methods All 1200 consecutive patients (age 74.2±10.2 years)
undergoing major non-cardiac surgery (37.4 % acute, 61.4 %
elective) during a period of 2.5 years while having at least one
CVD were enrolled. Details on medication, bleeding, cardio-
vascular complications and cause of death were registered.
Results In-hospital mortality was 3.9 % (versus 0.9 % mor-
tality among 17,740 patients without CVD). Cardiovascular
complications occurred in 91 (7.6 %) patients (with 37.4 %
case fatality). Perioperative bleeding occurred in 160 (13.3 %)
patients and was fatal in 2 (1.2 % case fatality). Multivariate
analysis revealed age, preoperative anaemia, history of chron-
ic heart failure, acute surgery and general anaesthesia predic-
tive of cardiovascular complications. For bleeding complica-
tions multivariate analysis found warfarin use in the last
3 days, history of hypertension and general anaesthesia as
independent predictive factors. Aspirin interruption before
surgery was not predictive for either cardiovascular or for
bleeding complications.
Conclusions Perioperative cardiovascular complications in
these high-risk elderly all-comer surgical patients with known
cardiovascular disease are relatively rare, but once they occur,
the case fatality is high. Perioperative bleeding complications
are more frequent, but their case fatality is extremely low.
Patterns of interruption of chronic aspirin therapy before ma-
jor non-cardiac surgery are not predictive for perioperative
complications (neither cardiovascular, nor bleeding). Simple
baseline clinical factors are better predictors of outcomes than
antithrombotic drug interruption patterns.
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Perioperative bleeding . Thrombosis . Antithrombotic
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Background
Interruption of antithrombotic therapy may be detrimental in
some patients. Meta-analysis of six studies on aspirin adher-
ence revealed that aspirin non-adherence/withdrawal was as-
sociated with a threefold higher risk of major adverse cardiac
events [1]. Non-cardiac surgery is frequently accompanied by
interruption of antithrombotic therapy and thus increases the
risk of stent thrombosis, myocardial ischaemia/infarction, and
death, especially soon after stent placement. The risk of sur-
gical haemorrhage is increased 20 % by aspirin or clopidogrel
alone and 50 % by dual antiplatelet therapy. Therefore,
some authors recommend to continue antiplatelet therapy
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throughout the perioperative period except when the risk of
bleeding outweighs the risk of acute stent thrombosis, while
others suggest 5–10 days interruption prior to surgery [2].
In moderate to high risk patients receiving acetylsalicylic
acid (ASA) and requiring non-cardiac surgery, the American
College of Clinical Pharmacy (ACCP) recommends ASA to
be continued around the time of surgery. Perioperative anti-
thrombotic management should be based on individual risk
assessment for thrombotic versus bleeding risk [3]. In patients
with semi-urgent surgery, the decision to prematurely stop
antiplatelet agents has to be taken after multidisciplinary con-
sultation, evaluating the individual thrombotic and bleeding
risk. Urgently needed surgery has to take place under full
antiplatelet therapy despite the increased bleeding risk. A
multidisciplinary approach for optimal antithrombotic and
haemostatic patient management is mandatory in this situation
[4]. Multiple studies have reported an independent association
between postoperative myocardial ischaemia and major ad-
verse cardiac events (MACE) and mortality, in both the short
and the long term [5].
Surgeons usually recommend to stop all antithrombotic
medication 1 week before surgery to prevent perioperative
bleeding. Such a strategy may increase the risk of periopera-
tive cardiovascular (frequently thrombotic / ischaemic) com-
plications. This study was designed to collect data from all
consecutive (non-selected) patients with known cardiovascu-
lar disease undergoing acute or elective major non-cardiac
surgery in order to analyse the bleeding / thrombotic risk
balance with focus on antithrombotic therapy.
Methods and patients
The study protocol was approved by the Ethics Committee of
the University Hospital Kralovske Vinohrady and by the
Czech Ministry of Health (IGA). The study is registered on
www.ClinicalTrials.gov under the identifier NCT01897220.
All departments performing major non-cardiac surgery in a
large tertiary university hospital participated: general surgery
(43.3 % patients), trauma and orthopaedic surgery (39.9 %),
urology (10.5 %), neurosurgery (5.5 %) and anaesthesiology
(0.8 %). The study was designed and coordinated by the
department of cardiology in the same hospital. All 1200
consecutive patients undergoing non-cardiac surgery
during the study period, while having known cardiovas-
cular disease, were enrolled (6.3 % of 18,951 patients
undergoing non-cardiac surgery during the study period
2011–2013).
The cardiovascular diagnoses at baseline (which formed
the only entry criteria for the study) were coronary artery
disease (n=820), atrial fibrillation (n=369), valvular disease
(n=176), prior stroke (n=127), presence of a prosthetic valve
(n=72), congestive heart failure (n=48), prior venous
thromboembolism (n=40) and cardiomyopathy (n=23).
Patients could have more than one (e.g. coronary artery dis-
ease and atrial fibrillation).
Acute (urgent or emergent, i.e. done during an acute un-
scheduled hospital admission) surgery was performed in
37.4 % of patients, elective (planned) surgery in the remaining
61.4 %, while in 1.2 % this was unspecified. General anaes-
thesia was used in 64.4 %, another type of anaesthesia
(epidural, subarachnoid) in 35.6 %.
The decision to stop antithrombotic medication preopera-
tively was left to the discretion of attending physicians
(usually a cardiologist or internist in collaboration with the
anaesthesiologist or surgeon). No specific recommendations
were prescribed by the study protocol.
The following data were recorded during the hospital stay:
ECG, medication (prior, during and after surgery), blood
counts, INR, creatinine, type of surgery, type of anaesthesia,
perioperative bleeding, perioperative cardiovascular compli-
cations (myocardial infarction, clinically manifest pulmonary
embolism or deep venous thrombosis, acute limb ischaemia,
acute stroke, new onset or recurrent heart failure) and the
cause of death. Perioperative bleeding was classified as (A)
fatal, (B) postoperative serious bleeding requiring surgical
revision, (C) postoperative serious bleeding requiring transfu-
sions but not revision, (D) intraoperative serious bleeding
complicating the procedure and (E) intraoperative bleeding
greater than usual prolonging the procedure. This classifica-
tion has significant similarities (Table 1) with the classification
of the International Society on Thrombosis and Haemostasis
(ISTH) [6]. We decided on a simple original classification of
bleeding, also in the light of certain criticism of the ISTH
classification [7].
Statistical analyses
Electronic case report forms were prepared with software
Oracle XE 10 G, data mining was done with Rapidminer
5.3, and data were exported to Microsoft Excel 2010.
Statistical analyses were performed using Statistica 8
Statsoft, SPSS 20.0.1 (IBM Corporation, 2011) and RStudio
0.96.331 (R Core Team, 2012).
Standard descriptive statistics were applied in the analysis;
categorical variables were described using absolute and rela-
tive frequencies, continuous variables using mean and stan-
dard deviation. Statistical significance of association between
categorised parameters was assessed using Fisher’s exact test
for both 2×2 and r×c contingency tables; for categorical
variables Pearson’s parametric coefficient of correlation was
used to assess the relationship among continuous parameters
[8]. Non-parametric Mann–Whitney was applied to test dif-
ferences in continuous variables among groups of patients.We
employed logistic regression models to assess the association
between potential predictors and selected binary coded
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endpoints (perioperative ischaemia, perioperative bleeding
and hospital mortality). Both univariate and multivariate re-
gression models were applied, resulting in age-adjusted and
multivariate-adjusted estimates of odds ratio with correspond-
ing 95 % confidence limits. All factors reaching p value <0.1
in the univariate models and their properly coded interaction
terms (if significant) entered the multivariate models as initial
pool of independent variables. A stepwise backward proce-
dure was applied to filter the final set of mutually independent
predictors providing the best model. The models used maxi-
mum likelihood estimation directly comparing the likelihood
L0 for the null model where all slope parameters are zero, with
the likelihood L1 of the fitted model. Significance of regres-
sion coefficients was tested with the help of the Wald statistic,
which is based on the asymptotic normality property of max-
imum likelihood estimates (tested against Chi-square distribu-
tion). All statistical tests were two-sided, and a value α <0.05
was considered to be a threshold for statistical significance in
all the comparisons made.
Results
Patient characteristics
The patients’ baseline characteristics are shown in Table 2.
The baseline chronic antithrombotic medication included
ASA (53.2 %), warfarin ± ASA (24.6 %), ASA + clopidogrel
(3.7%), clopidogrel alone (1.7 %), dabigatran (0.3 %) and
no antithrombotic agents (16.5 %). Other chronic med-
ication included beta-blockers (61.4 %), angiotensin-
converting enzyme inhibitors (54.1 %), statins (29.8 %),
diuretics (40.2 %), calcium channel blockers (19 %) and
nitrates (8.1 %).
Perioperative complications
Perioperative cardiovascular complications occurred in 91
(7.6 %) patients: acute or worsening heart failure (n=46),
acute myocardial infarction (n=24), venous thromboembo-
lism (n=15), acute limb ischaemia (n=11) and acute stroke
(n=3). Multivariate analysis revealed the following indepen-
dent risk factors for perioperative cardiovascular complica-
tions: age, acute surgery (versus elective), preoperative anae-
mia, history of previous PCI, history of chronic heart failure,
general anaesthesia (versus other types of anaesthesia). For
details see Table 3.
Perioperative bleeding occurred in 160 patients (13.3 %),
24 of them also had a cardiovascular complication. Bleeding
complications are shown in Table 1.Mean perioperative blood
loss was 149±375 ml (median 0, IQR 0–200). Red blood cell
transfusions were used in 12.5 %, frozen plasma in 5 %
patients, thrombocytes in 0.2 %. Multivariate analysis
found three independent predictors for bleeding compli-
cations: warfarin use in the last 3 days, history of
hypertension, and general anaesthesia. Surprisingly, the
length of aspirin interruption before surgery was not predic-
tive for either cardiovascular or for bleeding complications
(Table 4).
In-hospital mortality
Forty-seven patients died during the hospital stay (in-
hospital mortality 3.9 %). This is 4.3-times higher than
the 0.9 % mortality among the remaining 17,740 pa-
tients without heart disease who underwent major sur-
gery during the study period. The cause of death was
heart failure in 20 patients, pulmonary embolism in 7,
myocardial infarction in 3, sudden death in 2, acute
stroke in 2, and bleeding caused death in 2 patients.
Another cause of death was found in 7 patients. Thirty-
four of the 91 patients with perioperative cardiovascular
complications died (case fatality of cardiac patients with
perioperative cardiovascular complications 37.4 %).
Multivariate analysis revealed the following predictors
of in-hospital mortality: age, preoperative anaemia, his-
tory of chronic heart failure, acute surgery and general
anaesthesia (Table 5).
Table 1 Perioperative bleeding complications
Type of bleeding (PRAGUE-14 classification) Number of
patients
Type of bleeding (ISTH classification) Number of
patients
Fatal (type A) 2 Fatal (class 1) 2
Postoperative serious requiring surgical revision (type B) 16 Surgical requiring second intervention (class 4) 16
Postoperative serious requiring transfusions but not revision (type C) 25 Large surgical without second intervention (class 5) 35
Intraoperative serious complicating surgery (type D) 13
Intraoperative greater than usual, prolonging surgery (type E) 103
Extrasurgical leading to transfusions (class 3) 2
Bleeding in critical area or organ (class 2) 1
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Antithrombotic medication
Antithrombotic medication was stopped at a median
of 7 (aspirin, IQR 2–10), 4 (thienopyridine, IQR 1–8)
and 8 (warfarin, IQR 5–10) days prior to surgery.
Perioperative preventive low-dose anticoagulation
(most frequently enoxaparin) was used in 94.8 % of
patients.







Patients with both types
of complications
N = 973 67 136 24
Mean age 73.9±10.2 78.9±11.5 73.4±8.8 77.5±9.8
Female sex 434 (44.6 %) 31 (46.3 %) 52 (38.2 %) 10 (41.7 %)
Mean body weight 79.1±16.2 76.7±19.9 79.2±14.0 74.0±15.4
Diabetes mellitus 291 (29.9 %) 24 (35.8 %) 46 (33.8 %) 10 (41.7 %)
Hypertension 758 (77.9 %) 48 (71.6 %) 111 (81.6 %) 17 (70.8 %)
Chronic kidney disease 110 (11.3 %) 5 (7.5 %) 17 (12.5 %) 3 (12.5 %)
Chronic liver disease 44 (4.5 %) 2 (3.0 %) 5 (3.7 %) 3 (12.5 %)
Chronic pulmonary disease 121 (12.4 %) 13 (19.4 %) 15 (11.0 %) 6 (25.0 %)
Current tumour 152 (15.6 %) 11 (16.4 %) 20 (14.7 %) 4 (16.7 %)
Current haematological disease 30 (3.1 %) 1 (1.5 %) 6 (4.4 %) 1 (4.2 %)
Presence of vascular (coronary or peripheral) stent 195 (20.0 %) 12 (17.9 %) 36 (26.5 %) 9 (37.5 %)
History of any previous bleeding requiring treatment 9 (0.8 %) 1 (1.2 %) 0 (0 %) 0 (0 %)
Table 3 Univariate (age-adjusted) and multivariate-adjusted estimates of odds ratios of predictors associated with perioperative cardiovascular
complications as risk end-point
Predictors
(Risk and reference categories)
Univariate age-adjusted model Multivariate model
OR 95 % IC p* OR 95 % IC p*
Baseline characteristics
Age (continuous) Adjusting factor 1.05 1.03–1.08 <0.001 1.04 1.02–1.08 <0.001
Haemoglobin: below normal Reference: norm 2.26 1.45–3.52 <0.001 1.91 1.21–3.03 0.005
Platelets: above norm Reference: norm 2.55 1.19–5.47 0.016
Creatinine: above norm Reference: norm 1.81 1.16–2.82 0.009
Prior PCI: yes Reference: no 2.25 1.35–3.78 0.002 1.91 1.09–3.34 0.023
Chronic heart failure: yes Reference: no 3.12 1.48–6.57 0.003 2.80 1.26–6.22 0.011
Hypertension: yes Reference: no 0.61 0.37–0.99 0.043
Current smoking: yes Reference: no 2.05 1.03–4.11 0.042
Treatment
ASA interrupted ≤ 7 days Reference: > 7 days or no ASA 1.32 0.85–2.06 n.s.
Reference: > 7 days 1.87 0.84–4.13 n.s.
ASA interrupted ≤ 3 days Reference: > 3 days or no ASA 1.71 1.04–2.78 0.031
Reference: > 3 days 1.68 0.79–3.62 n.s.
Clopidogrel/Ticlopidin interrupted ≤ 3 days Reference: > 3 days 1.49 0.29–7.54 n.s.
Warfarin interrupted ≤ 3 days Reference: > 3 days or no Warfarin 2.61 1.16–5.86 0.020
Reference: > 3 days 2.94 0.93–9.23 n.s.
Surgery characteristics
Type of operation: acute Reference: elective 3.94 2.38–6.54 <0.001 4.00 2.41–6.66 <0.001
General anaesthesia: yes Reference: no 1.99 1.22–3.28 0.006 2.22 1.31–3.78 0.003
Blood loss greater than usual: yes Reference: no 2.08 1.21–3.59 0.008
p* Wald’s test
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Aspirin interruption
Among the patients with perioperative cardiovascular
complications, aspirin was stopped a median of 2.5 days
(IQR 0 – 6) before surgery (Table 6) while in patients
without cardiovascular complications aspirin was stopped a
median of 7 days (IQR 2 – 10) before surgery (p<0.001).
Among patients with perioperative bleeding, aspirin was
Table 4 Univariate (age-adjusted) and multivariate-adjusted estimates of odds ratios of potential predictors associated with perioperative bleeding as
risk end-point
Predictors
(risk and reference categories)
Univariate model Multivariate model
OR 95 % IC p* OR 95 % IC p*
History
Hypertension: yes Reference: no 1.54 0.99–2.41 0.045 1.61 1.03–2.53 0.037
Predictors
(risk and reference categories)
Univariate age-adjusted model Multivariate model
OR 95 % IC p* OR 95 % IC p*
Antithrombotic treatment
ASA therapy in the last 30 days: yes Reference: no 0.72 0.52–1.03 n.s.
Number of days before surgery when ASAwas interrupted: continuous 0.99 0.96–1.02 n.s.
Only for acute operation 1.01 0.92–1.10 n.s.
Only for elective operation 0.99 0.94–1.03 n.s.
ASA 7 days: interrupted ≤7 days Reference: >7 days or ASA not applied 0.74 0.51–1.07 n.s.
Reference: >7 days 0.97 0.57–1.62 n.s.
ASA 3 days: interrupted ≤3 days Reference: >3 days or ASA not applied 0.81 0.51–1.27 n.s.
Reference: >3 days 1.05 0.60–1.85 n.s.
Number of days before surgery when Clopidogrel/Ticlopidin
was interrupted: continuous
0.88 0.72–1.08 n.s.
Warfarin therapy in the last 30 days: yes Reference: no 1.56 1.09–2.24 0.017
Number of days before surgery when warfarin was interrupted: continuous 0.97 0.92–1.02 n.s.
Only for acute operation 0.89 0.77–1.04 n.s.
Only for elective operation 0.99 0.94–1.06 n.s.
Warfarin 3 days: interrupted ≤3 days Reference: >3 days or Warfarin not applied 3.12 1.62–6.01 0.002 3.11 1.61–6.02 0.001
Reference: >3 days 1.67 0.62–4.50 n.s.
Last INR: continuous 1.11 0.81–1.50 n.s.
Last INR >1.2 INR ≤1.2 0.89 0.47–1.69 n.s.
Surgery characteristics
Type of operation: acute Reference: elective 1.27 0.91–1.78 n.s.
General anaesthesia: yes Reference: no 1.47 1.02–2.11 0.037 1.47 1.01–2.14 0.040
*Wald’s test
Table 5 Univariate (age-adjusted) and multivariate-adjusted estimates of odds ratios of potential predictors associated with hospital mortality as risk
endpoint
Predictors
(Risk and reference categories)
Univariate age-adjusted model Multivariate model
OR 95 % IC p* OR 95 % IC p*
Basic characteristics
Age (continuous) Adjusting factor 1.05 1.03–1.08 <0.001 1.05 1.02–1.09 0.004
Haemoglobin: under norm Reference: norm 2.89 1.57–5.33 0.001 2.57 1.36–4.87 0.004
Chronic heart failure: yes Reference: no 4.22 1.76–10.10 0.001 4.25 1.69–10.68 0.002
Type of surgery: acute Reference: elective 2.81 1.44–5.50 0.003 3.00 1.53–5.88 0.001
General anaesthesia: yes Reference: no 3.61 1.68–7.74 0.001 4.14 1.85–9.24 0.001
*Wald’s test
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stopped a median of 7 days (IQR 2 – 12) before surgery while
in patients without bleeding aspirin was stopped a median of
7 days (IQR 2 – 10) before surgery (n.s.). Surprisingly, the
median time of preoperative aspirin interruption was 7 days
(IQR 2–12) among patients with bleeding complications ver-
sus 2.5 days (IQR 0–6) in those with cardiovascular compli-
cations (p=0.001).
Warfarin interruption
There was no significant difference (p=0.80) in the median
length of warfarin interruption between patients with periop-
erative bleeding (7 days, IQR 3 – 9.5) versus patients with
perioperative cardiovascular complications (7.5 days, IQR
2.5-10). However, warfarin interruption ≤3 days before sur-
gery was an independent predictor of bleeding complications.
Discussion
The initial idea of our study was to see the results of this
registry and then (if there proved to be some trend for less
cardiovascular events in patients with continuing ASA treat-
ment) consider a randomised study comparing the two strate-
gies (a one-week ASA interruption vs. no interruption at all).
As no trends were observed, we decided not to initiate a
randomised study. In our current view (knowing the registry
results) such a study would most likely be futile.
The independent predictors of in-hospital mortality (age,
preoperative anaemia, history of chronic heart failure, acute
surgery and general anaesthesia) are one of the important
findings of this study. The relative importance of bleeding
events versus cardiovascular events is reflected in the fact that
the number of deaths related to cardiovascular complications
was 34 vs. only 2 deaths related to bleeding. Perioperative
cardiovascular complications are usually more serious and
more difficult to treat than most bleeding complications [9, 10].
One study detected perioperative myocardial ischaemia in
40.5 % of patients. However, major adverse cardiac events
occurred in only 8 % [11]. A large study in patients with
atherosclerosis or at risk for it undergoing non-cardiac surgery
found myocardial infarction in 5 % and troponin release in
8 % of patients [12]. In general surgical patients with docu-
mented coronary artery disease or at high risk for it, Filipovic
et al. found troponin elevation in 16% and myocardial ischae-
mia on continuous ECG in 46 % of patients [13].
The role and timing of interruption of antiplatelet agents
before non-cardiac surgery has been studied by several au-
thors. The STRATAGEM study randomised 291 patients un-
dergoing elective non-cardiac surgery to either aspirin or
placebo starting 10 days before surgery. The study did not
find a significant difference in the number of major compli-
cations between the aspirin vs. placebo groups [14]. Aspirin
increased the rate of bleeding complications in a meta-analysis
by factor 1.5; however it did not lead to more severe bleeding
complications with the exception of intracranial surgery and
transurethral prostatectomy [15]. A single-centre study
analysed 516 ASA-treated patients undergoing elective non-
cardiac surgery: 289 patients had antiplatelet therapy stopped
in the perioperative period. The decision to cease antiplatelet
therapy, which occurred commonly, did not appear to be
guided by perioperative cardiac risk stratification [16]. A
Swedish study concluded that in high-risk patients undergoing
non-cardiac surgery, perioperative aspirin reduced the risk of
major adverse cardiac events without increasing bleeding
complications [17].
The role of clopidogrel was investigated by Burdess et al.:
in patients with critical limb ischaemia, perioperative dual
Table 6 Length of antithrombotic drugs interruption in subgroups per complication type
How many days before surgery the drug was interrupted in subgroups per complication types
N= Mean SD Median Percentile 25 Percentile 75 Min Max
ASA No complications 563 7.6 7.9 7 2 10 0 90
CV complications 38 4.1 4.8 2.5 0 6 0 18
Bleeding 67 10.3 13.8 7 2 12 0 90
Both types of complications 10 4.4 6.6 1 0 6 0 20
Clopidogrel No complications 44 6.1 6.1 5 1 8 0 24
CV complications 6 6.5 7.9 3 0 15 0 18
Bleeding 11 3.5 4.3 1 0 7 0 12
Both types of complications 1 11 11 11 11 11 11
Warfarin No complications 191 9.4 7.9 8 5 11 0 60
CV complications 16 8.4 7.3 7.5 2.5 10 0 23
Bleeding 40 9 10.1 7 3 9.5 0 46
Both types of complications 5 5 6 3 1 6 0 15
Neth Heart J (2014) 22:372–379 377
antiplatelet therapy reduces biomarkers of atherothrombosis
without causing unacceptable bleeding [18].
Our study seems to confirm that previous PCI with coro-
nary stent implantation is an independent risk factor for peri-
operative complications. Savonitto et al. [19] and Motovska
[20] recommend stratifying the risk of surgical bleeding and
cardiac ischaemic events in order to manage perioperative
antiplatelet therapy whenever surgery cannot be postponed.
The situation is even more difficult when patients are
treated with long-term oral anticoagulation. The analysis of
1024 patients with warfarin therapy interruption before minor
surgery found 7 post-procedure thromboembolic events and
23 clinically significant bleedings [21]. Another study on 556
patients with mechanical prosthetic valves evaluated the risk
of thrombotic and bleeding complications when warfarin was
stopped 4–5 days prior to a surgical procedure and re-started
after the procedure as soon as haemostasis was assured. The 3-
month incidence of thromboembolism was 0.9 %. None of
those few cases were fatal. The cumulative incidence of major
bleeding was 3.6 % and was fatal in 0.2 % [22]. Douketis et al.
analysed 650 consecutive patients with a mechanical heart
valve, chronic atrial fibrillation, or embolic stroke who re-
quired interruption of warfarin therapy because of an invasive
procedure. Warfarin was stopped 5 or 6 days before the
procedure, and patients received subcutaneous dalteparin
starting 3 days before the procedure. Two patients died due
to thromboembolism, 2 patients suffered non-fatal thrombo-
embolic complications, there were 6 major bleeding episodes
and 32 patients had episodes of increased wound-related
blood loss [23].
The POISE-2 study (www.clinicaltrials.gov, identifier
NCT01082874) is a large trial investigating the effectiveness
of aspirin and clonidine versus placebo (factorial 2×2 design)
in 10,000 patients with coronary artery disease undergoing
non-cardiac surgery. The aim is to provide data to guide the
decision-making on aspirin in the perioperative setting. The
hope is that in the future perioperative antiplatelet therapy will
be based on clinical evidence rather than on consensus.
Our study limitations
This study was designed to include all-comers with various
cardiovascular diseases undergoing major surgery with no
exclusion criteria. Over one-third of the patients were admit-
ted (and operated) acutely without sufficient time to withdraw
the antithrombotic medication. Some of our findings may be
influenced by this fact. The all-comers design is a strength of
this study (giving a real-life picture) but simultaneously a
weakness (causing heterogenicity of patients, their medica-
tions and surgical procedures). This study has no power to
assess dual antiplatelet therapy in this setting or to produce
any recommendations regarding patients with coronary stents
or with prosthetic valves due to the relatively low number of
these patients within the studied population.
As the study aim was to describe the real-life situation in
nonselected consecutive patients, we did not prescribe any
prospective criteria for when to stop the antithrombotic ther-
apy. The number of patients on warfarin was 296 and thus the
study was not powered to analyse this group. Very few pa-
tients were on the newer antithrombotic agents (dabigatran).
The relatively low number of patients with perioperative
complications is clinically encouraging, but statistically is
certainly a limitation for the interpretation of the study results.
Another serious limitation for the interpretation of our
study results is the fact that most patients received low-dose
perioperative anticoagulation to prevent venous thromboem-
bolism. This might further complicate the interpretation of our
data.
Conclusions
Perioperative cardiovascular complications in these high-risk
elderly all-comer surgical patients with known cardiovascular
disease are relatively rare, but once they occur, the case fatality
is high. Perioperative bleeding complications are more fre-
quent, but their case fatality is extremely low. Patterns of
interruption of chronic aspirin therapy before major non-
cardiac surgery are not predictive for perioperative complica-
tions (neither cardiovascular, nor bleeding). Simple baseline
clinical factors are better predictors of outcomes than anti-
thrombotic drug interruption patterns.
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